cereport
Small moleculeexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 1996 (NCT00001502)
Timeline
Indications
Mechanism of action
- Bradykinin B2 receptorAGONIST
BDKRB2 agonist
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc(C[C@@H](CN[C@@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CO)NC(=O)[C@H](Cc2cccs2)NC(=O)CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H]2CCCN2C(=O)[C@@H](N)CCCNC(=N)N)cc1- Mol. weight
- 1098.3 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2105864 ↗
Also known as
- cereport
- cereport
- cereport
- labradimil
- labradimil
- labradimil
- lobradimil
- lobradimil
- lobradimil
- l-prolinamide, l-arginyl-l-prolyl-trans-4-hydroxy-l-prolyl-3-(2-thienyl)-l-alanylglycyl-l-seryl-n-02-004-0((((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-0(((4-methoxyphenyl)methyl)ethyl)-, 0s-(r*,r*)-
- rmp 7
- rmp-7
- rmp-7
- rmp-7
- rmp-7
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00005602 | Phase 1 | Feb 1, 2001 | Children's National Medical Center, National Cancer Institute (NCI) |
| NCT00002316 | Phase 1 | Nov 2, 1999 | Alkermes |
| NCT00019422 | Phase 2 | Mar 1, 1998 | National Cancer Institute (NCI), University of Pittsburgh |
| NCT00001502 | Phase 1 | Apr 1, 1996 | National Cancer Institute (NCI) |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 3 | 3 | 2 | 1996 |
| Alkermes | For profit | 1 | 1 | 1 | 1999 |
| Children's National Medical Center | Academic/Hospital | 1 | 0 | 1 | 2001 |
| University of Pittsburgh | Academic/Hospital | 1 | 0 | 1 | 1998 |
4 organizations
Page 1 / 1